LEVELS OF UNINVOLVED IMMUNOGLOBULIN PREDICT CLINICAL STATUS AND PROGRESSION FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS
(Abstract release date: 05/21/15)
EHA Library. Berenson J. 06/12/15; 102918; PB1876
Disclosure(s): Institute for Myeloma & Bone Cancer ResearchHematology/Oncology
Mr. James Berenson
Contributions
Contributions
Abstract
Abstract: PB1876
Type: Publication Only
Background
The levels of monoclonal immunoglobulins (M-Igs) are used to monitor multiple myeloma (MM). HevyLite® +(HLC) assays are able to discriminate between uninvolved and M-Ig levels.
Aims
We evaluated the levels of involved and uninvolved HLC, their ratios and differences and their relationship to outcomes among 189 MM patients.
Methods
Serum samples were analyzed using the HLC assays, and results were correlated with clinical status (complete response (CR), ≥ partial response (PR), < partial response, and progressive disease (PD)). Comparisons were made using student’s t, Mann-Whitney, and Fisher’s tests. PFS was calculated using Kaplan-Meier analysis. All tests were double-tailed and P-values determined.
Results
The patients were 62% IgG and 38% IgA with a median age of 66 years, ?2 microglobulin 3.27 mg/L, albumin 3.8 g/dl, and median follow up of 72.5 months. Patients with PD had higher involved HLC levels, lower uninvolved HLC levels, higher ratios of involved/uninvolved HLCs and greater differences between them compared with patients with ≥ PR (all with P<0.0001). A higher proportion of patients in ≥ PR had normal uninvolved HLC levels than patients with
Summary
We show that involved/uninvolved HLC ratios, differences between them, involved and uninvolved HLC levels correlate with clinical status for MM patients. Patients with normal uninvolved levels or normal involved HLC levels have a longer PFS.
Keyword(s): Multiple myeloma, Survival
Session topic: Publication Only
Type: Publication Only
Background
The levels of monoclonal immunoglobulins (M-Igs) are used to monitor multiple myeloma (MM). HevyLite® +(HLC) assays are able to discriminate between uninvolved and M-Ig levels.
Aims
We evaluated the levels of involved and uninvolved HLC, their ratios and differences and their relationship to outcomes among 189 MM patients.
Methods
Serum samples were analyzed using the HLC assays, and results were correlated with clinical status (complete response (CR), ≥ partial response (PR), < partial response, and progressive disease (PD)). Comparisons were made using student’s t, Mann-Whitney, and Fisher’s tests. PFS was calculated using Kaplan-Meier analysis. All tests were double-tailed and P-values determined.
Results
The patients were 62% IgG and 38% IgA with a median age of 66 years, ?2 microglobulin 3.27 mg/L, albumin 3.8 g/dl, and median follow up of 72.5 months. Patients with PD had higher involved HLC levels, lower uninvolved HLC levels, higher ratios of involved/uninvolved HLCs and greater differences between them compared with patients with ≥ PR (all with P<0.0001). A higher proportion of patients in ≥ PR had normal uninvolved HLC levels than patients with
Summary
We show that involved/uninvolved HLC ratios, differences between them, involved and uninvolved HLC levels correlate with clinical status for MM patients. Patients with normal uninvolved levels or normal involved HLC levels have a longer PFS.
Keyword(s): Multiple myeloma, Survival
Session topic: Publication Only
Abstract: PB1876
Type: Publication Only
Background
The levels of monoclonal immunoglobulins (M-Igs) are used to monitor multiple myeloma (MM). HevyLite® +(HLC) assays are able to discriminate between uninvolved and M-Ig levels.
Aims
We evaluated the levels of involved and uninvolved HLC, their ratios and differences and their relationship to outcomes among 189 MM patients.
Methods
Serum samples were analyzed using the HLC assays, and results were correlated with clinical status (complete response (CR), ≥ partial response (PR), < partial response, and progressive disease (PD)). Comparisons were made using student’s t, Mann-Whitney, and Fisher’s tests. PFS was calculated using Kaplan-Meier analysis. All tests were double-tailed and P-values determined.
Results
The patients were 62% IgG and 38% IgA with a median age of 66 years, ?2 microglobulin 3.27 mg/L, albumin 3.8 g/dl, and median follow up of 72.5 months. Patients with PD had higher involved HLC levels, lower uninvolved HLC levels, higher ratios of involved/uninvolved HLCs and greater differences between them compared with patients with ≥ PR (all with P<0.0001). A higher proportion of patients in ≥ PR had normal uninvolved HLC levels than patients with
Summary
We show that involved/uninvolved HLC ratios, differences between them, involved and uninvolved HLC levels correlate with clinical status for MM patients. Patients with normal uninvolved levels or normal involved HLC levels have a longer PFS.
Keyword(s): Multiple myeloma, Survival
Session topic: Publication Only
Type: Publication Only
Background
The levels of monoclonal immunoglobulins (M-Igs) are used to monitor multiple myeloma (MM). HevyLite® +(HLC) assays are able to discriminate between uninvolved and M-Ig levels.
Aims
We evaluated the levels of involved and uninvolved HLC, their ratios and differences and their relationship to outcomes among 189 MM patients.
Methods
Serum samples were analyzed using the HLC assays, and results were correlated with clinical status (complete response (CR), ≥ partial response (PR), < partial response, and progressive disease (PD)). Comparisons were made using student’s t, Mann-Whitney, and Fisher’s tests. PFS was calculated using Kaplan-Meier analysis. All tests were double-tailed and P-values determined.
Results
The patients were 62% IgG and 38% IgA with a median age of 66 years, ?2 microglobulin 3.27 mg/L, albumin 3.8 g/dl, and median follow up of 72.5 months. Patients with PD had higher involved HLC levels, lower uninvolved HLC levels, higher ratios of involved/uninvolved HLCs and greater differences between them compared with patients with ≥ PR (all with P<0.0001). A higher proportion of patients in ≥ PR had normal uninvolved HLC levels than patients with
Summary
We show that involved/uninvolved HLC ratios, differences between them, involved and uninvolved HLC levels correlate with clinical status for MM patients. Patients with normal uninvolved levels or normal involved HLC levels have a longer PFS.
Keyword(s): Multiple myeloma, Survival
Session topic: Publication Only
{{ help_message }}
{{filter}}